Trevi Therapeutics Inc
$ 13.33
-4.31%
05 Jun - close price
- Market Cap 1,892,590,000 USD
- Current Price $ 13.33
- High / Low $ 13.93 / 13.31
- Stock P/E N/A
- Book Value 1.43
- EPS -0.32
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -0.34 %
- 52 Week High 16.12
- 52 Week Low 5.41
About
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious neurology-mediated conditions. The company is headquartered in New Haven, Connecticut.
Analyst Target Price
$23.90
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-03-17 | 2025-11-13 | 2025-08-07 | 2025-05-08 | 2025-03-18 | 2024-11-06 | 2024-08-08 | 2024-05-07 | 2024-03-20 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.09 | -0.06 | -0.08 | -0.09 | -0.09 | -0.11 | -0.13 | -0.12 | -0.11 | -0.08 | -0.08 | -0.07 |
| Estimated EPS | -0.073 | -0.0985 | -0.1 | -0.1 | -0.09 | -0.1171 | -0.12 | -0.11 | -0.09 | -0.09 | -0.09 | -0.08 |
| Surprise | -0.017 | 0.0385 | 0.02 | 0.01 | 0 | 0.0071 | -0.01 | -0.01 | -0.02 | 0.01 | 0.01 | 0.01 |
| Surprise Percentage | -23.2877% | 39.0863% | 20% | 10% | 0% | 6.0632% | -8.3333% | -9.0909% | -22.2222% | 11.1111% | 11.1111% | 12.5% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TRVI
2026-06-05 21:10:47
Trevi Therapeutics shareholders have approved significant changes, including an amended 2019 Stock Incentive Plan, increasing authorized common stock from 200 million to 400 million shares, and electing Michael Heffernan as a Class I director. These moves aim to enhance talent attraction and retention, improve governance, and provide financing flexibility. Analysts currently rate TRVI stock as a "Buy" with a $23 price target, while an AI analyst from TipRanks assesses it as Neutral due to pre-revenue risks despite improved funding visibility.
2026-06-05 08:10:47
Trevi Therapeutics director David P. Meeker was granted 35,000 nonstatutory stock options with an exercise price of $13.45 per share, expiring on June 2, 2036. The options will vest on the earlier of the one-year anniversary of the June 3, 2026 grant date or the next annual shareholder meeting, contingent on his continued service. This transaction is classified as an acquisition of derivative securities for compensation purposes, increasing Meeker's direct derivative holdings to 35,000 options.
2026-06-04 19:41:01
Trevi Therapeutics director Anne Vanlent was granted 35,000 nonstatutory stock options with an exercise price of $13.45 per share, expiring on June 2, 2036. These options are scheduled to fully vest on the earlier of one year from the June 3, 2026 grant date or the next annual stockholders meeting, provided she continues her service. This award is part of routine compensation and not an open-market purchase.
2026-06-04 19:41:01
Trevi Therapeutics director Dominick Colangelo was granted a nonstatutory stock option to purchase 35,000 shares of common stock at an exercise price of $13.45 per share. This grant, dated June 3, 2026, is scheduled to fully vest on the earlier of the first anniversary of the grant date or the next annual stockholders' meeting, provided he remains a director, employee, or consultant. Following this transaction, Colangelo directly holds 35,000 stock options.
2026-06-04 19:41:01
Trevi Therapeutics (TRVI) announced that its stockholders approved several governance and capital measures at the 2026 annual meeting. Key approvals include the doubling of authorized common shares from 200,000,000 to 400,000,000 and the addition of 8,000,000 shares to the 2019 Stock Incentive Plan. These changes provide the company with greater flexibility for future equity issuances, financing, acquisitions, and employee compensation.
2026-06-02 19:10:18
Trevi Therapeutics stock recently hit a 52-week low of $13.68, despite analysts setting price targets between $20 and $30 and the company showing a 129.41% appreciation over the past year. The company reported a strong cash position of $334 million in Q1 2026 and plans to begin a pivotal program for Haduvio, with initial data expected in 2027. Stifel has maintained a Buy rating with an $18 price target, supporting the company's financial stability and clinical progress.
